Bavarian Nordic
Research Bavarian Nordic (BAVA.CO) on Bullrun: market cap DKK 16.74B, P/E 11.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBAVA.CO
- ExchangeXCSE
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyDKK
- Market capDKK 16.74B
- P/E11.4
- Financial periodQ1 2026
- RevenueDKK 1.06B
- Net incomeDKK 16.95M
- Free cash flow-DKK 810.26M
- Gross margin44.8%
Valuation Snapshot
latest market cap is DKK 16.74B; P/E is 11.4.
Peer valuation comparison
Latest P/E is 11.41x versus a Healthcare sector median of 24.64x (53.7% below).
Latest P/E is 11.41x versus a Denmark median of 17.65x (35.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 6.24B | DKK 1.38B | DKK 1.36B | 48.8% | n/a | DKK 1.71B | DKK 130.87M | DKK 12.87B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | DKK 16.74B | 11.4 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 DKK.
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bavarian Nordic's market cap?
Bavarian Nordic's market capitalization is DKK 16.74B.
What is Bavarian Nordic's P/E ratio?
Bavarian Nordic's price-to-earnings (P/E) ratio is 11.4.
What does Bavarian Nordic do?
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses.